Corinna Marie Reyes-rayas, CADC I | |
2080 S E St, San Bernardino, CA 92408-2773 | |
(909) 388-9191 | |
Not Available |
Full Name | Corinna Marie Reyes-rayas |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 2080 S E St, San Bernardino, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013297316 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Corinna Marie Reyes-rayas, CADC I 2080 S E St, San Bernardino, CA 92408-2773 Ph: (909) 388-9191 | Corinna Marie Reyes-rayas, CADC I 2080 S E St, San Bernardino, CA 92408-2773 Ph: (909) 388-9191 |
News Archive
The Center for Strategic & International Studies (CSIS) "wanted to learn more about how women leaders in Africa are bringing new attention to women's health and empowerment in their own countries, and to bring those voices into the discussion about U.S. policy priorities for women's global health," so a small CSIS team traveled to Malawi and Zambia in December 2012, Janet Fleischman and Julia Nagel of CSIS write in the group's Smart Global Health blog.
At a time when access to prompt treatment might affect survival, a large new study finds that African-American and Hispanic women newly diagnosed with breast cancer often face delays in care of more than a month.
Results from a randomized, open-label phase III trial suggest that a combination cream of halometasone and fusidic acid reduces symptoms of eczema to a similar degree to a betamethasone and neomycin sulphate cream, but is more effective at treating infected lesions.
"As we honor the enormous impact women have on their families and communities worldwide, we also call on lawmakers to do more for global maternal and newborn health," Former White House Press Secretaries Mike McCurry and Dana Perino write in a post in The Hill's "Congress Blog," marking International Women's Day, which was celebrated on Thursday.
IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a one-year, multi-center study demonstrates the safety and durability of its proprietary MicroPulse technology as a treatment for glaucoma.
› Verified 4 days ago